Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for Primary Antifungal Prophylaxis

Micro-Abstract Patients treated with azacitidine who previously received intensive chemotherapy are at a highest risk for fungal infection (invasive aspergillosis; P = .015).

Saved in:
Bibliographic Details
Published inClinical lymphoma, myeloma and leukemia Vol. 14; no. 1; pp. 80 - 86
Main Authors Falantes, Jose F, Calderón, Cristina, Márquez-Malaver, Francisco J, Aguilar-Guisado, Manuela, Martín-Peña, Almudena, Martino, María L, Montero, Isabel, González, Jose, Parody, Rocío, Pérez-Simón, Jose A, Espigado, Ildefonso
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.02.2014
Subjects
Acute Myeloid Leukemia
Adult
Aged
Aged, 80 and over
Antifungal Agents - therapeutic use
Antimetabolites, Antineoplastic - therapeutic use
Aspergillosis
Azacitidine
Azacitidine - therapeutic use
Hematology, Oncology and Palliative Medicine
Humans
Incidence
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - microbiology
Middle Aged
Myelodysplastic Syndrome
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - microbiology
Prophylaxis
Retrospective Studies
Salvage Therapy - methods
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Azacitidine
Aspergillosis
Prophylaxis
Online AccessGet full text

Cover

More Information
Summary:Micro-Abstract Patients treated with azacitidine who previously received intensive chemotherapy are at a highest risk for fungal infection (invasive aspergillosis; P = .015).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2013.09.014